Perioperative Anti-Fibrotic Treatment Prevents Acute Exacerbation of Idiopathic Pulmonary Fibrosis After Lung Cancer Surgery

Perioperative Anti-Fibrotic Treatment Prevents Acute Exacerbation of Idiopathic Pulmonary Fibrosis After Lung Cancer Surgery

Background: The surgical treatment of concomitant lung cancer in patients with idiopathic pulmonary fibrosis is challenging due to the risk of life-threatening complications such as acute exacerbation development in the perioperative period. Few studies have investigated the role of anti-fibrotic dr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Stefano Bongiolatti, Alberto Salvicchi, Elisabetta Rosi, Elena Bargagli, Giovanni Mugnaini, Alessandro Gonfiotti, Federico Lavorini, Paolo Spagnolo, Andrea Dell’Amore, Federico Rea, Luca Voltolini
Format:	Article
Language:	English
Published:	MDPI AG 2024-11-01
Series:	Life
Subjects:	anti-fibrotic treatment pirfenidone nintedanib lung surgery acute exacerbation
Online Access:	https://www.mdpi.com/2075-1729/14/11/1506
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prevention and Treatment of Peritoneal Dialysis-Associated Fibrosis with Intraperitoneal Anti-Fibrotic Therapy in Experimental Peritoneal Fibrosis
by: Chiao-Yin Sun, et al.
Published: (2025-01-01)

Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study
by: Olcay Aycicek, et al.
Published: (2025-02-01)

Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
by: Hikmet COBAN, et al.
Published: (2025-06-01)

Prognostic significance of acute exacerbations and usual interstitial pneumonia in fibrotic interstitial lung disease
by: Yun Zhang, et al.
Published: (2025-07-01)

Pulmonary fibrosis complicated by lung cancer: bibliometric analysis from 2004 to 2024 - research status, trends and future directions
by: Boyang Li, et al.
Published: (2025-04-01)

Combination Treatment of Timosaponin BII and Pirfenidone Attenuated Pulmonary Fibrosis Through Anti-Inflammatory and Anti-Fibrotic Process in Rodent Pulmonary Fibrosis Model and Cellular Epithelial–Mesenchymal Transition Model
by: Xuebin Shen, et al.
Published: (2025-04-01)

Longitudinal changes in KL6 levels predict acute exacerbation in fibrotic interstitial lung disease
by: Akihiro Shiroshita, et al.
Published: (2025-07-01)

Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone
by: Tomohiko Yagi, et al.
Published: (2025-02-01)

Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis
by: Nesrin Ocal, et al.

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases
by: Tao Wang, et al.
Published: (2025-04-01)

Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland
by: Sebastian Majewski, et al.
Published: (2025-06-01)

Ways to improve the diagnosis and treatment of interstitial lung disease associated with systemic sclerosis in the Siberian Federal District (materials of the advisory board of rheumatologists and pulmonologists from December 08, 2019)
by: L. I. Alekseeva, et al.
Published: (2020-10-01)

Treatable traits in idiopathic pulmonary fibrosis: focus on respiratory tract infections—a systematic review and a meta-analysisResearch in context
by: Zsombor Matics, et al.
Published: (2025-01-01)

The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
by: Stefano Kette, et al.
Published: (2025-03-01)

Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis
by: Yiting Qiu, et al.
Published: (2025-07-01)

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France
by: Emilie Clay, et al.
Published: (2019-01-01)

Fibrosis in PCLS: comparing TGF-β and fibrotic cocktail
by: Carlos Machahua, et al.
Published: (2025-01-01)

Blockade of the pro‐fibrotic reaction mediated by the miR‐143/‐145 cluster enhances the responses to targeted therapy in melanoma
by: Serena Diazzi, et al.
Published: (2022-02-01)

Oncologic Outcomes of Thoracoscopic Segmentectomy in Patients with High-Grade Adenocarcinoma Pattern
by: Stefano Bongiolatti, et al.
Published: (2025-02-01)

The hamstring stretch angle: a screening and monitoring tool for canine fibrotic myopathy
by: Kate Elizabeth Birdwhistell, et al.
Published: (2025-05-01)

TWO-PHASE DYNAMICS OF BONE MARROW MULTIPOTENT MESENCHYMAL STROMAL CELLS (MMSC) ACTION ON LIVER AT MODELING OF FIBROTIC HEPATITIS
by: N. A. Onishchenko, et al.
Published: (2011-06-01)

Fibrotic Hypersensitivity Pneumonitis: A Diagnostic Challenge Leading to Lung Transplantation
by: Maria-Daniela Mot, et al.
Published: (2025-05-01)

Increased perivascular fibrosis and pro-fibrotic cellular transition in intramyocardial blood vessels in myocardial infarction patients
by: Zhu Jiang, et al.
Published: (2024-12-01)

Natural products for anti-fibrotic therapy in idiopathic pulmonary fibrosis: marine and terrestrial insights
by: Meiting Ma, et al.
Published: (2025-05-01)

INTERSTITIAL LUNG DISEASES: KEY TARGETS FOR THERAPY
by: N. A. Shostak, et al.
Published: (2018-06-01)

The pulmoprotective effects of pirfenidone against paraquat-induced pulmonary toxicity: a systematic review
by: Sajjad Sadeghi, et al.
Published: (2025-06-01)

COPD exacerbation: factors influencing hospitalization duration
by: Gashynova K.Yu.
Published: (2015-03-01)

Single-cell RNA-seq reveals immune cell heterogeneity and increased Th17 cells in human fibrotic skin diseases
by: Cheng-Cheng Deng, et al.
Published: (2025-01-01)

Understanding the Gaps in the Reporting of COPD Exacerbations by Patients: A Review
by: Paul Jones, et al.
Published: (2024-12-01)

Management of Asthma and COPD Exacerbations in Adults in the ICUKey PointsClinical QuestionClinical Question
by: Stephen A. Mein, MD, et al.
Published: (2025-03-01)

Estimated prevalence and incidence of hypersensitivity pneumonitis in Japan
by: Tsukasa Okamoto, et al.
Published: (2025-01-01)

Comparing survival outcomes of anti-fibrotic therapy for idiopathic pulmonary fibrosis with and without emphysema: a multi-center real-world study from Taiwan
by: Yu-Hung Fang, et al.
Published: (2025-08-01)

Bronchoalveolar Lavage Derived Fibroblasts From Interstitial Lung Disease Patients: A Chance to Exploit 2D/3D Model of Pulmonary Fibrosis In Vitro
by: Paolo Giannoni, et al.
Published: (2025-07-01)

Variability of blood eosinophil count and prognosis of COPD exacerbations
by: Sandra Martínez-Gestoso, et al.
Published: (2021-01-01)

Jumi extract lowered the expression of inflammatory and fibrotic components in human renal tubular epithelial cells induced by high glucose through inhibiting long noncoding RNA RMRP gene
by: Cheng Tao, et al.
Published: (2022-02-01)

COPD exacerbation: anthropometric characteristics of patients and the frequency of hospital admissions
by: Gashynova K.Y.
Published: (2014-11-01)

Risk factors for prolonged hospitalization as a marker for difficult-to-manage exacerbations of chronic obstructive lung disease (COPD): the DiMECO Study
by: Dorina Esendağlı, et al.
Published: (2024-11-01)

Asthma Exacerbation in Children: A Practical Review
by: Lin-Shien Fu, et al.
Published: (2014-04-01)

Glial heterotopia of the lip: A rare presentation
by: Mehmet Dadaci, et al.
Published: (2016-01-01)

Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis
by: Jingran Xu, et al.
Published: (2025-08-01)